Background. Ceftolozane/tazobactam (C/T) is a novel antimicrobial with activity against pathogens causing complicated intra-abdominal infections (cIAIs), including extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and drug-resistant P. aeruginosa. The efficacy and safety of C/T -+ metronidazole (MTZ) compared with meropenem (MEM) were evaluated in a randomized, double-blind phase 3 trial in hospitalized patients with cIAI. This analysis provides information on cIAI involving P. aeruginosa, a pathogen poorly described in cIAI.
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Methods. Hospitalized patients with cIAI were randomized to 4-14 days of intravenous (IV) C/T (1.5 g) + MTZ (500 mg) every 8 hours or IV MEM (1 g every 8 hours). Baseline intra-abdominal cultures were obtained. The primary efficacy endpoint was the clinical response at the test-of-cure (TOC) visit 26-30 days after the start of study therapy.
Results. In the microbiological intent-to-treat (MITT) population (N = 806), P. aeruginosa was isolated in 72 (8.9%) patients (38 C/T + MTZ, 34 MEM); the incidence of P. aeruginosa in North America was 18%. P. aeruginosa was more frequently associated with polymicrobial infection (94% vs 65%). The highest incidence of P. aeruginosa occurred in patients with infections arising from the colon (14%) or appendix (11%). P. aeruginosa infections were less likely to be hospital-acquired (2.8% vs 7.1%) but occurred more commonly in those receiving prior antibiotic therapy (65% vs 57%). C/T and MEM were highly active in vitro against P. aeruginosa, with a minimum inhibitory concentration against 90% of pathogens (MIC 90 ) of 2 µg/mL and 4 µg/mL, respectively. Clinical cure rates in the microbiologically evaluable patients with P. aeruginosa were 100% (25/25) and 96% (27/28) for C/T + MTZ and MEM, respectively.
Conclusion. In this phase 3 study in hospitalized patients with cIAI, P. aeruginosa was isolated in 8.9% of MITT patients. Interestingly, P. aeruginosa was most commonly isolated in community-acquired infections of the colon and appendix. 
